← Back to Search

Radioisotope Therapy

Rhenium Re 188 P2045 for Lung Cancer

Phase 1 & 2

Recruiting

Research Sponsored by Andarix Pharmaceuticals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Has histologically or cytologically documented Non-Small-Cell Lung Cancer (NSCLC) or Small-Cell Lung Cancer (SCLC) and has advanced or recurrent IIIb or IV NSCLC (adenocarcinoma, squamous cell carcinoma, large cell, mixed or not otherwise specified) or disseminated or recurrent SCLC or any lung cancer which has local recurrence

Has documentation of progressive disease following prior chemotherapy or who refused to receive standard chemotherapy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to one year post study completion

Awards & highlights

Study Summary

This trialwill test the max safe dose of an experimental drug, monitoring closely for bad side effects before increasing dose.

Who is the study for?

This trial is for adults with advanced or recurrent lung cancer (NSCLC or SCLC) who have seen their disease progress after chemotherapy, or those who refused standard chemo. They must have a measurable tumor that hasn't been treated with radiation, or one that has grown significantly if previously irradiated.Check my eligibility

What is being tested?

The study is testing the safety of different doses of an experimental drug called Rhenium Re 188 P2045 in lung cancer patients. The goal is to find the highest dose patients can take without serious side effects by starting low and gradually increasing.See study design

What are the potential side effects?

Since Rhenium Re 188 P2045 is experimental, specific side effects are being studied. However, potential risks may include typical reactions to new cancer drugs such as nausea, fatigue, allergic reactions, and possibly others determined during the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My lung cancer is advanced, recurrent, or has spread.

Select...

My cancer has worsened after chemotherapy or I chose not to undergo standard chemotherapy.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to one year post study completion

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to one year post study completion

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to one year post study completion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Maximum tolerated dose of Rhenium 188 P2045

Progression free survival in treated patients

Safety of Technetium Tc 99m P2045 and Rhenium Re 188 P2045

Trial Design

1Treatment groups

Experimental Treatment

Group I: Arm 1Experimental Treatment1 Intervention

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Andarix PharmaceuticalsLead Sponsor

Andarix Study DirectorStudy DirectorAndarix Pharmaceuticals

Media Library

Non-Small Cell Lung Cancer Research Study Groups: Arm 1

Non-Small Cell Lung Cancer Clinical Trial 2023: Rhenium Re 188 P2045 Highlights & Side Effects. Trial Name: NCT00100256 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals have been recruited for participation in this experiment?

"Affirmative. The clinicaltrial.gov registry states that this experiment, which was initially published on January 1st 2004, is still recruiting participants. 60 patients are sought from 2 medical settings to be included in the trial."

Answered by AI

Is there still capacity for additional participants in this research project?

"Affirmative. According to records on clinicaltrials.gov, this research trial is presently enrolling participants; it was initially posted in January of 2004 and most recently updated at the end of October 2022. There are 60 spots available between two sites."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy

2004. "Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00100256.

All > Non Small Cell Lung Cancer > Paid Studies Maryland